Cell Therapy Catapult Recruits Four Non-Executive Directors

Cell Therapy Catapult Recruits Four Non-Executive Directors

31 Jan 2013

The Cell Therapy Catapult (CT Catapult), which is focused on the development of the UK cell therapy industry to increase the nation's health and wealth, is pleased to announce the appointment of four high calibre non-executive directors to its Board. The NEDs, Tim Edwards, Nick Higgins, and Professors Marc Turner and Michael Whitaker, bring with them a wealth of industry, academic and clinical expertise, plus cell therapy knowledge. With Chairman Dr John Brown CBE, FRSE, CEO Keith Thompson and Technology Strategy Board Representative Dr Zahid Latif, they complete the Board.

Michael Whitaker is Professor of Physiology and Dean of Research and Innovation in the Faculty of Medical Sciences at Newcastle, with the brief of developing research and of furthering links with the commercial sector.  He is also Co-Director of the joint Durham/Newcastle/NHS North East England Stem Cell Institute. Also joining the Board is Marc Turner, Professor of Cellular Therapy at the University of Edinburgh and Medical Director at the Scottish National Blood Transfusion Service. Marc's work includes translational research in stem cell therapy and adoptive immunotherapy.

Nick Higgins, currently Executive Director of Corporate Development at medical devices company Consort Medical plc, has spent over 30 years in the life sciences industry, with extensive knowledge of UK and US markets. In his various roles he has raised over £100m from investors, including the £60m IPO of regenerative medicine company Intercytex Group in 2006. As an entrepreneur, Tim Edwards is another valuable addition to the Board. He is Chairman of Atopix Therapeutics Ltd and Oxagen Ltd, which are developing small molecule drugs for allergic asthma and atopic disease, and Chairman of the Management Board of ProtAffin AG. Previously, Tim was CEO of Cellzome Inc, a drug discovery company focused on chemoproteomics. It raised over $150m in collaboration upfront payments and was sold in 2012 to GlaxoSmithKline plc. Tim is also Chairman of the BioIndustry Association, and has a number of other non-executive roles in the biotechnology and public sectors.

Dr John Brown, Chair of the CT Catapult, said: 'I'm pleased to welcome Michael, Marc, Tim and Nick to our Board. Their industrial, academic and medical experience and networks will be invaluable as we execute our strategy to help grow a UK cell therapy industry.'

Simon Edmonds, Director of the Technology Strategy Board's Catapults Programme, added 'The Catapult programme has been established to capture and translate the UK's expertise and innovative capacity in areas such as cell therapy. The Cell Therapy Catapult has made significant progress since inception and we are pleased to see the completion of its Board with the appointment of these experienced and high quality individuals.'

View the full press release including notes to editors here

 

Last updated on Friday 01 February 2013 at 14:22

More like this

Copyright © 2013